|
MRPL15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.06069638919848E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.39519573250891E-11 |
| Normal-vs-Stage2 |
6.263000E-01 |
| Normal-vs-Stage3 |
9.64117674584486E-13 |
| Normal-vs-Stage4 |
1.69908531688634E-12 |
| Stage1-vs-Stage2 |
6.681700E-03 |
| Stage1-vs-Stage3 |
4.628800E-01 |
| Stage1-vs-Stage4 |
3.796400E-03 |
| Stage2-vs-Stage3 |
3.655200E-03 |
| Stage2-vs-Stage4 |
2.182700E-04 |
| Stage3-vs-Stage4 |
2.844300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.23598917159507E-13 |
| Normal-vs-AfricanAmerican |
2.17950000047651E-07 |
| Normal-vs-Asian |
1.48550000078629E-08 |
| Caucasian-vs-AfricanAmerican |
5.911000E-01 |
| Caucasian-vs-Asian |
8.331600E-01 |
| AfricanAmerican-vs-Asian |
7.451800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.55409998600942E-09 |
| Normal-vs-Female |
1.07429953821736E-10 |
| Male-vs-Female |
8.720600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.01839647825841E-11 |
| Normal-vs-Age(41-60Yrs) |
1.36779476633819E-11 |
| Normal-vs-Age(61-80Yrs) |
2.779700E-03 |
| Normal-vs-Age(81-100Yrs) |
4.442600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.151400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.166200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.962000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.814060E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.896800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.296400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.926600E-01 |
| Classical-VS-Follicular |
1.564090E-04 |
| Classical-VS-Other |
8.965600E-01 |
| Classical-VS-Normal |
1.62536650805123E-12 |
| Tall-VS-Follicular |
5.770200E-04 |
| Tall-VS-Other |
8.450000E-01 |
| Tall-VS-Normal |
6.54289999957314E-09 |
| Follicular-VS-Other |
3.051400E-01 |
| Follicular-VS-Normal |
9.218400E-02 |
| Other-VS-Normal |
1.342410E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.49000000115862E-08 |
| Normal-vs-N1 |
6.88338275267597E-15 |
| N0-vs-N1 |
2.28569999999317E-05 |
|
|
